ProShares UltraShort NASDAQ Biotechnology
9 hedge funds and large institutions have $16.2M invested in ProShares UltraShort NASDAQ Biotechnology in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 10 closing their positions.
662% more call options, than puts
Call options by funds: $3.26M | Put options by funds: $428K
4% more capital invested
Capital invested by funds: $15.6M → $16.2M (+$639K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
44% less funds holding
Funds holding: 16 → 9 (-7)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$9.82M |
| 2 |
KC
Kingfisher Capital
Charlotte,
North Carolina
|
+$1.54M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$255K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$244K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$2.41M |
| 2 |
FAM
Fred Alger Management
New York
|
-$1.71M |
| 3 |
FTUS
Flow Traders U.S.
New York
|
-$1.07M |
| 4 |
Jane Street
New York
|
-$670K |
| 5 |
BMO
Beck Mack & Oliver
New York
|
-$602K |
BIS Hedge Fund Activity: Q4 2014 in Review
9 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2014, worth a combined $16.2M — up 4.1% from $15.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BIS and 5 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Highland Capital Management (Texas), adding an estimated $9.82M. The largest seller was Healthcare Value Capital, exiting entirely with an estimated $2.41M sold.
- 9 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2014, down from 16 in Q3 2014.
- Funds reported $16.2M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2014, up 4.1% quarter-over-quarter.
- 5 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2014 and 10 closed out, a net change of -5 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2014 was Highland Capital Management (Texas), an estimated $9.82M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2014 was Healthcare Value Capital, an estimated $2.41M sold.
Based on aggregated 13F filings for Q4 2014.